Clinical Trial Update: An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CKD-501 as monotherapy for glycemic control in adults with type 2 diabetes mellitus. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CKD-501

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED